THE ROLE OF TP53 MUTATIONS IN LOW-RISK MDS PATIENTS

被引：0
|
作者：
Belickova, M. [1 ]
Vesela, J. [1 ]
Jonasova, A. [2 ]
Kohlmann, A. [3 ]
Stara, E. [1 ]
Planetova, B. [1 ]
Valka, J. [1 ]
Zemanova, Z. [2 ]
Brezinova, J. [1 ]
Michalova, K. [1 ,2 ]
Cermak, J. [1 ]
机构：
[1] Inst Hematol & Blood Transfus, CR-12820 Prague, Czech Republic
[2] Gen Univ Hosp, Prague, Czech Republic
[3] Munich Leukemia Lab, Munich, Germany
来源：
HAEMATOLOGICA | 2014年 / 99卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P320
引用
收藏
页码：91 / 91
页数：1
相关论文
共 50 条
  • [1] TP53 mutations in low-risk MDS patients with isolated del(5q)
    Belickova, M.
    Vesela, J.
    Cermak, J.
    Dostalova, M. M.
    Krejcik, Z.
    Stara, E.
    Zemanova, Z.
    Jonasova, A.
    LEUKEMIA RESEARCH, 2013, 37 : S27 - S28
  • [2] TP53 mutations and MDS - not as easy as it seems
    Haase, D.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 7 - 8
  • [3] The Prognostic Significance of TP53 Mutations for Overall Outcome in Lower-Risk MDS Patients
    Belickova, Monika
    Vesela, Jitka
    Jonasova, Anna
    Stara, Eliska
    Planetova, Barbora
    Zemanova, Zuzana
    Brezinova, Jana
    Mikulenkova, Dana
    Cermak, Jaroslav
    BLOOD, 2014, 124 (21)
  • [4] Presence of new mutations in the TP53 gene in patients with low-risk myelodysplastic syndrome: Two case reports
    Duarte F.B.
    Lemes R.P.G.
    Dos Santos T.E.D.J.
    Barbosa M.C.
    De Vasconcelos J.P.L.
    Rocha-Filho F.D.
    Zalcberg I.
    Coutinho D.
    Figueiredo M.F.
    Carlos L.B.
    De Vasconcelos P.R.L.
    Journal of Medical Case Reports, 11 (1) : 1 - 4
  • [5] Response to azacitidine is independent of TP53 mutations in higher-risk MDS
    Mueller-Thomas, C.
    Rudelius, M.
    Wolf, P.
    Schmidt, B.
    Platzbecker, U.
    Germing, U.
    Peschel, C.
    Gotze, K.
    ONKOLOGIE, 2012, 35 : 31 - 31
  • [6] Prognostic Value of TP53 Gene Mutations in Higher Risk MDS Treated with Azacitidine
    Bally, Cecile
    Ades, Lionel
    Renneville, Aline
    Preudhomme, Claude
    Mozziconacci, Marie-Joelle
    de The, Hugues
    Lehmann-Che, Jacqueline
    Fenaux, Pierre
    BLOOD, 2012, 120 (21)
  • [7] Isolated TP53 Mutations Portend Worse Prognosis in MDS and AML Compared to TP53 Mutations with Concurrent Myeloid-Associated Mutations
    Hussaini, Mohammad
    Abuel-Haija, Mohammad
    Padron, Eric
    David, Sallman
    Song, Jinming
    LABORATORY INVESTIGATION, 2018, 98 : 524 - 525
  • [8] Isolated TP53 Mutations Portend Worse Prognosis in MDS and AML Compared to TP53 Mutations with Concurrent Myeloid-Associated Mutations
    Hussaini, Mohammad
    Abuel-Haija, Mohammad
    Padron, Eric
    David, Sallman
    Song, Jinming
    MODERN PATHOLOGY, 2018, 31 : 524 - 525
  • [9] THE PROGNOSTIC SIGNIFICANCE OF TP53 MUTATIONS IN MDS PATIENTS WITH DEL(5Q)
    Belickova, M.
    Vesela, J.
    Jonasova, A.
    Planetova, B.
    Valka, J.
    Mikulenkova, D.
    Zemanova, Z.
    Brezinova, J.
    Michalova, K.
    Cermak, J.
    LEUKEMIA RESEARCH, 2015, 39 : S22 - S23
  • [10] Role of TP53 Mutations in Vulvar Carcinomas
    Choschzick, Matthias
    Hantaredja, Widianto
    Tennstedt, Pierre
    Gieseking, Frederike
    Woelber, Linn
    Simon, Ronald
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY, 2011, 30 (05) : 497 - 504
12345